Rodriguez, E.; Pei, G.; Zhao, Z.; Kim, S.T.; German, A.; Robinson, P.
Erratum: Rodriguez et al. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers 2021, 13, 3871. Cancers 2021, 13, 5178.
https://doi.org/10.3390/cancers13205178
AMA Style
Rodriguez E, Pei G, Zhao Z, Kim ST, German A, Robinson P.
Erratum: Rodriguez et al. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers 2021, 13, 3871. Cancers. 2021; 13(20):5178.
https://doi.org/10.3390/cancers13205178
Chicago/Turabian Style
Rodriguez, Emma, Guangsheng Pei, Zhongming Zhao, Sang T. Kim, Alexis German, and Prema Robinson.
2021. "Erratum: Rodriguez et al. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers 2021, 13, 3871" Cancers 13, no. 20: 5178.
https://doi.org/10.3390/cancers13205178
APA Style
Rodriguez, E., Pei, G., Zhao, Z., Kim, S. T., German, A., & Robinson, P.
(2021). Erratum: Rodriguez et al. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers 2021, 13, 3871. Cancers, 13(20), 5178.
https://doi.org/10.3390/cancers13205178
